embody vs altRx vs welludr: The Budget GLP-1 Trio
Last updated: Sep 1, 2026
Medically reviewed by Francheska Capistrano, RMT, MPH · Medical Content Reviewer
Medically reviewed on Reviewed · Written by Treatments Hub Research Team
We may earn a commission from links on this page - it never affects our rankings (how we stay objective).
Here’s the short version
These three providers own the budget end of the compounded GLP-1 market, and they get there by different routes: welludr's $41 rewards a 12-month plan, embody's $49 is flat with zero commitment, and altRx's $89 adds the option to switch to brand-name Ozempic or Zepbound later. Same active ingredients across all three - the matrix below is really a comparison of commitment terms, logistics and optionality.
Compounded GLP-1 from $49/month; not FDA-approved, free expedited delivery
Visit embodyembody vs altRx vs welludr: side by side
Real published prices and terms - the differences that actually decide this matchup.
| embody | altRx | welludr | |
|---|---|---|---|
| Semaglutide | $49/mo, flat at every dose | $89/mo (reg. $199), flat at every dose | $41/mo (12-month plan), same price at every dose |
| Tirzepatide | $99/mo | $149/mo (reg. $299) | $71/mo |
| Billing & commitment | Monthly - no commitment, cancel anytime | Monthly - pause or cancel anytime; Buy Now, Pay Later | Monthly billing - best rate locks on a 12-month plan |
| Shipping | Free expedited delivery, tracked & insured; no timeline guaranteed | Free nationwide delivery | Free, every 4 weeks, discreet packaging |
| Support | Licensed doctors, medical director & nursing team | Licensed provider review (physician, PA, or NP) | Medical Weight-Care Coach on every plan |
| Guarantee / refund | Partial refund if not approved (unused portion less services rendered) | - | Weight-loss warranty (terms on site) |
| Standout | LegitScript-certified; 503A pharmacies | Brand-name shelf: Ozempic $1,149 · Zepbound $1,249 · Wegovy $1,579 | 1M+ patients; board-certified specialists |
Our verdict
Pick by your commitment appetite. Committed for a year and price-first: welludr's $41 is unbeatable. Want the freedom to stop anytime: embody's flat $49 with free expedited delivery and a partial-refund-if-not-approved policy is the cleanest deal in the market. Think brand-name might be in your future: altRx is the only one of the three with a brand shelf, and its BNPL spreads the cost. There's no wrong answer here on legitimacy - all three run licensed-provider review and regulated pharmacies.
embody vs altRx vs welludr: FAQs
Which of embody, altRx and welludr is cheapest?
welludr has the lowest headline price at $41/month for compounded semaglutide, but that rate locks on a 12-month plan. embody charges a flat $49/month with no commitment, and altRx $89/month with pause-anytime terms and Buy Now, Pay Later. On tirzepatide: welludr $71, embody $99, altRx $149.
Do all three require a prescription?
Yes. All three are telehealth providers where a licensed clinician reviews your medical intake and decides whether GLP-1 treatment is appropriate - approval is not automatic at any of them. Medication is dispensed through licensed pharmacies.
Which ships fastest?
embody ships free, tracked and insured, with no delivery timeline guaranteed in its Terms. altRx offers free nationwide delivery on standard timelines, and welludr ships free every 4 weeks in discreet packaging aligned to its dosing cycle.
Break it down two at a time
The head-to-head comparisons between these providers.
Medical disclaimer
This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.
Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.
Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.
Sources & medical references
Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.
- 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
- 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
- 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
- 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
- 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
- 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
- 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)
